Tokyo, Japan - Institute of Medicinal Molecular Design, Inc. (IMMD) announced today that it has successfully completed the phase I clinical trial of IMD-1041, a small molecule compound originally designed and developed by IMMD, in the United Kingdom and confirmed its safety profile as a novel drug candidate for further development.
